Tivic Health Systems, Inc
- Biotech or pharma, therapeutic R&D
- Medical device or technology
Tivic Health is a diversified, late-stage immunotherapeutic company.
The company’s lead product candidate, recently in-licensed, is a late-stage TLR5 agonist, Entolimod™. Unlike common G-CSF oncology drugs, Entolimod has been shown to treat both GI and bone marrow and has been demonstrated to have both reparative and prophylactic benefits via activation of NF-kB pathway. Funding from BARDA, DoD, NASA. Phase III clinical trials are complete for first indication--acute radiation syndrome (ARS). Additional indications in neutropenia, lymphocyte exhaustion and immunosenescence.
Tivic Health has also developed new neuromodulation techniques to non-invasively engage vagus nerve activity, modulating autonomic and immune systems. Tivic has demonstrated meaningful impact on heart rate variability as well as gamma and theta wave activity.
Company has previously commercialized an FDA approved consumer product sold online retailers and through commercial distributors.
Address
FremontCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}